Charles Craig (C Craig)

Publication Activity (10 Years)

Years Active: 2018-2021
Publications (10 Years): 4

Top Topics

Antiretroviral Therapy

Dendritic Cells

Top Venues

Antiviral chemistry & chemotherapy

Research Virology Consulting Ltd.

The Queen's University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Research Virology Consulting Ltd.

United Kingdom

Director

Pfizer Inc

United Kingdom

Associate Research Fellow :: R&D

GlaxoSmithKline

United Kingdom

Senior Investigator and Group Leader :: International Clinical Virology

Roche Products Ltd

United Kingdom

Research Scientist :: R&D

Education History

The Queen's University

United Kingdom

PHD :: Immunobiology and Microbiology

The Queen's University

United Kingdom

MSC :: Immunobiology and Microbiology

Publications

M E Lewis, B Jubb, P Simpson, A Lopatukhin, D Kireev, M Bobkova, Charles Craig, E van der Ryst, M Westby, S L Butler
Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc. Antiviral chemistry & chemotherapy 29 (2021)
M E Lewis, P Simpson, J Mori, B Jubb, J Sullivan, L McFadyen, E van der Ryst, Charles Craig, D L Robertson, M Westby
V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens. Antiviral chemistry & chemotherapy 29 (2021)
Becky Jubb, Marilyn Lewis, Lynn McFadyen, Paul Simpson, Julie Mori, Phylinda Chan, Barry Weatherley, Elna van der Ryst, Mike Westby, Charles Craig
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials. Antiviral chemistry & chemotherapy 27 (2019)
Marilyn Lewis, Julie Mori, Jonathan Toma, Mike Mosley, Wei Huang, Paul Simpson, Roy Mansfield, Charles Craig, Elna van der Ryst, David L Robertson, Jeannette M Whitcomb, Mike Westby
Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials. PloS one 13 (12) (2018)